

ESMO Virtual Advanced Course on Clinical Questions in Prostate Cancer

Programme

**ESMO VIRTUAL
ADVANCED COURSE**

28-29 SEPTEMBER 2021

Co-Chairs

Elena Castro, Spain

Bertrand Tombal, Belgium

ESMO VIRTUAL ADVANCED COURSE PROGRAMME CLINICAL QUESTIONS IN PROSTATE CANCER

28-29 September 2021

CO-CHAIRS: Elena Castro, Spain
Bertrand Tombal, Belgium

SPEAKERS: Boris Y. Alekseev, Russian Federation
Alexander Govorov, Russian Federation
Ken Herrmann, Germany
Laura-Maria Krabbe, Germany
Pernelle Lavaud, France
Vsevolod Matveev, Russian Federation
Maria José Ribal, Spain
Thomas Zilli, Switzerland

LEARNING OBJECTIVES

- To understand essentials in the assessment and the value of multidisciplinary management of prostate cancer
- To learn about state-of-the-art advances in treatment of prostate cancer
- To learn the principles of management of advanced prostate cancer through direct exposure to real clinical scenarios

ACCREDITATION

The programme of this virtual event has been accredited with **6 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered CEST (Central European Summer Time)

Tuesday, 28 September 2021

09:00-09:05 **Welcome and course overview**

5' Elena Castro, ES
Bertrand Tombal, BE

09:05-09:45 **Session 1**
State-of-the-art in prostate cancer diagnostics

15' PSMA based diagnostics: The future of imaging
Ken Herrmann, DE

15' Biology: Clinical genomics in prostate cancer management
Elena Castro, ES

10' Discussion
Faculty

09:45-10:25 **Session 2**
High risk localized prostate cancer

15' Role of radiotherapy: Recent advances in RT modalities (*including hypofractionation, brachytherapy, SABR*)
Thomas Zilli, CH

15' High risk localized disease: Integrating drugs with local treatments
Laura-Maria Krabbe, DE

10' Discussion
Faculty

10:25-10:40 **Break**

10:40-11:35 **Session 3**
Intermediate situation of advanced prostate cancer

15' Rising PSA: nmHSPC
Alexander Govorov, RU

15' Oligometastatic prostate cancer
Thomas Zilli, CH

15' M0 Castrate Resistant Prostate Cancer (CRPC): What are our latest options?
Bertrand Tombal, BE

10' Discussion
Faculty

11:35- 12:15	Session 4 Metastatic prostate cancer - Part 1
15'	Metastatic hormone sensitive prostate cancer: State of the art management in 2021 Boris Y. Alekseev, RU
15'	Metastatic CRPC: Standard of care in 2021 (<i>including bone targeting agents</i>) Vsevolod Matveev, RU
10'	Discussion Faculty

Wednesday, 29 September 2021

09:00-09:25	Session 5 Metastatic prostate cancer - Part 2
15'	Metastatic CRPC: What's on the horizon – new treatments (PARP inhibitors, BiTE) Pernelle Lavaud, FR
10'	Discussion Faculty
09:25-11:55	Workshops sessions Three workshops sessions 10' Introduction based on clinical cases presented by speakers 30' Discussion
Workshop 1 45'	Localized prostate cancer Alexander Govorov, RU Thomas Zilli, CH
10:10-10:25	Break
Workshop 2 45'	High risk/locally advanced prostate cancer Laura-Maria Krabbe, DE Maria José Ribal, ES
Workshop 3 45'	Metastatic prostate cancer Elena Castro, ES Vsevolod Matveev, RU
11:55-12:00	Conclusion and farewell Bertrand Tombal, BE Elena Castro, ES